NEXTECH VI ONCOLOGY SCSP 13D and 13G filings for ARS Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2023-02-14 4:35 pm Unchanged | 2022-12-31 | 13G | ARS Pharmaceuticals, Inc. SPRY | NEXTECH VI ONCOLOGY SCSP | 1,910,029 2.000% | 0 (Unchanged) | Filing |
| 2021-02-16 4:01 pm Purchase | 2020-12-31 | 13G | ARS Pharmaceuticals, Inc. SPRY | NEXTECH VI ONCOLOGY SCSP | 1,910,029 5.500% | 1,910,029 (New Position) | Filing |